8-K
filed May 8, 2023, 7:59 PM ET
ticker FLNA
CIK 0001069530
other material
confidence high
sentiment neutral
materiality 0.15
Cassava Sciences shareholder vote fails to approve officer liability limitation
FILANA THERAPEUTICS, INC.
- Directors Robert Z. Gussin (7.1M for) and Richard J. Barry (6.7M for) elected to three-year terms.
- Proposal to limit officer liability failed; received 87% of votes cast but not a majority of outstanding shares (7.8M for vs 24.8M outstanding).
- Non-employee director compensation program approved with 7.8M for, 986K against.
- Ernst & Young ratified as auditor for FY2023 with 24.1M for, 532K against.
- Advisory say-on-pay approved (6.6M for, 2.1M against); frequency set to every one year (8.2M votes).
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
FILANA THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on frequency of advisory votes on executive compensation at the 2023-05-04 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-05-04
Exact text from the filing
Proposal Six – A non-binding, advisory vote on the frequency of non-binding, advisory votes on the executive compensation for the Company’s named executive officers was approved for every “one” year based upon the following votes: Every one year Every two years Every three years Abstain Broker Non -Vote 8,154,665 151,642 336,776 318,422 15,811,623
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
FILANA THERAPEUTICS, INC. shareholders approved Company's Non-employee Director Compensation Program at the 2023-05-04 meeting.
- Outcome
- passed
- Meeting
- 2023-05-04
Exact text from the filing
Proposal Three – The Company’s Non-employee Director Compensation Program was approved based upon the following votes: For Against Abstain Broker Non -Vote 7,758,563 985,705 217,237 15,811,623
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
FILANA THERAPEUTICS, INC. shareholders approved Appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-05-04 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-04
Exact text from the filing
Proposal Four – The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023, was ratified based upon the following votes: For Against Abstain 24,121,878 532,002 119,248
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
FILANA THERAPEUTICS, INC. shareholders rejected Amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company at the 2023-05-04 meeting.
- Proposal
- charter amendment
- Outcome
- failed
- Meeting
- 2023-05-04
Exact text from the filing
Proposal Two – An amendment to the Company’s Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company , which received approximately 87% of the votes cast, did not receive votes greater than 50% of outstanding common shares as of the Record Date and was thus not approved based upon the following votes: For Against Abstain Broker Non -Vote 7,795,721 944,106 221,678 15,811,623
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
FILANA THERAPEUTICS, INC. shareholders approved 2022 executive compensation for named executive officers (non-binding advisory vote) at the 2023-05-04 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-04
Exact text from the filing
Proposal Five – The 2022 executive compensation for the Company’s named executive officers was approved, on a non-binding advisory vote, based upon the following votes: For Against Abstain Broker Non -Vote 6,604,493 2,105,630 251,382 15,811,623
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
FILANA THERAPEUTICS, INC. shareholders approved Election of two nominees to the Board of Directors for a three-year term at the 2023-05-04 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-04
Exact text from the filing
Proposal One – Two (2) nominees for election to the Board of Directors were elected to serve for a three-year term, and until their successors are duly elected and qualified, based upon the following votes: Director For Withheld Broker Non-Vote Robert Z. Gussin, Ph.D. 7,116,958 1,844,547 15,811,623 Richard J. Barry 6,675,746 2,285,759 15,811,623
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.